81 citations
,
February 2000 in “Anti-cancer drugs” In this pilot study, Doxil at 60 mg/m² every 4 weeks showed activity against hormone-refractory prostate cancer but was limited by severe mucocutaneous toxicities.
63 citations
,
February 2013 in “Human cell” In this study using an animal model, researchers found that PEGL-DOX, unlike DOX, causes Hand-Foot Syndrome due to reactive oxygen species interacting with skin tissue, leading to skin-specific inflammatory responses.
November 2024 in “International Journal of Molecular Sciences” This study developed caffeine-loaded nanoparticles coated with ultradeformable liposomes for better hair follicle delivery, showing non-cytotoxicity and potential to reduce oxidative stress in DHT-damaged cells, suggesting an alternative treatment for androgenetic alopecia.
522 citations
,
January 2001 in “Cancer investigation” This review describes the unique pharmacological profile and clinical applications of pegylated liposomal doxorubicin, emphasizing its role in Kaposi's sarcoma and recurrent ovarian cancer, but reports no new clinical results.
This chapter reviews the structure, pharmacokinetics, and clinical applications of PEGylated liposomes and reports no new research findings.